JP2023537943A5 - - Google Patents

Info

Publication number
JP2023537943A5
JP2023537943A5 JP2023509499A JP2023509499A JP2023537943A5 JP 2023537943 A5 JP2023537943 A5 JP 2023537943A5 JP 2023509499 A JP2023509499 A JP 2023509499A JP 2023509499 A JP2023509499 A JP 2023509499A JP 2023537943 A5 JP2023537943 A5 JP 2023537943A5
Authority
JP
Japan
Prior art keywords
sequence
seq
rnai construct
sense strand
antisense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023509499A
Other languages
English (en)
Japanese (ja)
Other versions
JP7880324B2 (ja
JP2023537943A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/045784 external-priority patent/WO2022036126A2/en
Publication of JP2023537943A publication Critical patent/JP2023537943A/ja
Publication of JP2023537943A5 publication Critical patent/JP2023537943A5/ja
Priority to JP2025282055A priority Critical patent/JP2026049002A/ja
Application granted granted Critical
Publication of JP7880324B2 publication Critical patent/JP7880324B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023509499A 2020-08-13 2021-08-12 MARC1発現を阻害するためのRNAiコンストラクト及び方法 Active JP7880324B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025282055A JP2026049002A (ja) 2020-08-13 2025-12-25 MARC1発現を阻害するためのRNAiコンストラクト及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063065190P 2020-08-13 2020-08-13
US63/065,190 2020-08-13
US202163214016P 2021-06-23 2021-06-23
US63/214,016 2021-06-23
PCT/US2021/045784 WO2022036126A2 (en) 2020-08-13 2021-08-12 RNAi CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025282055A Division JP2026049002A (ja) 2020-08-13 2025-12-25 MARC1発現を阻害するためのRNAiコンストラクト及び方法

Publications (3)

Publication Number Publication Date
JP2023537943A JP2023537943A (ja) 2023-09-06
JP2023537943A5 true JP2023537943A5 (cg-RX-API-DMAC7.html) 2024-08-21
JP7880324B2 JP7880324B2 (ja) 2026-06-25

Family

ID=77640774

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023509499A Active JP7880324B2 (ja) 2020-08-13 2021-08-12 MARC1発現を阻害するためのRNAiコンストラクト及び方法
JP2025282055A Pending JP2026049002A (ja) 2020-08-13 2025-12-25 MARC1発現を阻害するためのRNAiコンストラクト及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025282055A Pending JP2026049002A (ja) 2020-08-13 2025-12-25 MARC1発現を阻害するためのRNAiコンストラクト及び方法

Country Status (17)

Country Link
US (1) US20220047621A1 (cg-RX-API-DMAC7.html)
EP (1) EP4196584A2 (cg-RX-API-DMAC7.html)
JP (2) JP7880324B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230046319A (cg-RX-API-DMAC7.html)
CN (1) CN116194119A (cg-RX-API-DMAC7.html)
AU (1) AU2021326521A1 (cg-RX-API-DMAC7.html)
CA (1) CA3190868A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000407A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023002966A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230126A (cg-RX-API-DMAC7.html)
IL (1) IL300360A (cg-RX-API-DMAC7.html)
JO (1) JOP20230030A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023001786A (cg-RX-API-DMAC7.html)
PE (1) PE20230993A1 (cg-RX-API-DMAC7.html)
TW (1) TW202221124A (cg-RX-API-DMAC7.html)
UY (1) UY39382A (cg-RX-API-DMAC7.html)
WO (1) WO2022036126A2 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220264823A1 (en) * 2021-02-24 2022-08-25 Syngenta Crop Protection Ag Soybean variety
US20220338438A1 (en) * 2021-04-21 2022-10-27 Syngenta Crop Protection Ag A soybean variety
US11655473B2 (en) * 2021-05-28 2023-05-23 Novo Nordisk A/S Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (MARC1) expression
CA3225054A1 (en) * 2021-07-08 2023-02-12 Sun Woo Hong Rnai agent targeting marc1 gene, and use thereof
US20230240241A1 (en) * 2022-01-28 2023-08-03 Pioneer Hi-Bred International, Inc. Soybean variety 5pryl83
US20230240232A1 (en) * 2022-01-28 2023-08-03 Pioneer Hi-Bred International, Inc. Soybean variety 5psym14
US12635649B2 (en) * 2022-02-16 2026-05-26 Syngenta Crop Protection Ag Soybean line EC2020472
KR20250043473A (ko) * 2022-07-27 2025-03-28 이-테라퓨틱스 피엘씨 핵산 화합물
US20240268301A1 (en) * 2023-02-10 2024-08-15 Pioneer Hi-Bred International, Inc. Soybean variety 5ptcn76
WO2024186171A1 (ko) * 2023-03-08 2024-09-12 올릭스 주식회사 비만의 예방 또는 치료용 RNAi 제제 및 이를 이용한 병용 요법
EP4680249A1 (en) * 2023-03-16 2026-01-21 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of mitochondrial amidoxime reducing component 1 (marc1), pharmaceutical compositions thereof, and methods of use
CN118853663A (zh) * 2023-04-28 2024-10-29 北京福元医药股份有限公司 用于抑制marc1基因表达的双链核糖核酸及其修饰物、缀合物和用途
US12690546B1 (en) * 2024-02-28 2026-07-28 Pioneer Hi-Bred International, Inc. Soybean variety 5PQRB49
US20250268198A1 (en) * 2024-02-28 2025-08-28 Pioneer Hi-Bred International, Inc. Soybean variety 5pgbu05
US12653137B2 (en) * 2024-02-28 2026-06-16 Pioneer Hi-Bred International, Inc. Soybean variety 5PPZM06
US12702109B1 (en) * 2024-02-28 2026-08-11 Pioneer Hi-Bred International, Inc. Soybean variety 5PDKJ08
US12690549B2 (en) * 2024-02-28 2026-07-28 Pioneer Hi-Bred International, Inc. Soybean line 5PHSB14
US12677793B2 (en) * 2024-02-28 2026-07-14 Pioneer Hi-Bred International, Inc. Soybean line 5PAKS02
US12702108B1 (en) * 2024-02-28 2026-08-11 Pioneer Hi-Bred International, Inc. Soybean variety 5PVEA23
US12685285B2 (en) * 2024-02-28 2026-07-21 Pioneer Hi-Bred International, Inc. Soybean variety 5PYSG46
US12653134B2 (en) * 2024-02-28 2026-06-16 Pioneer Hi-Bred International, Inc. Soybean variety 5PEVE11
US12690547B1 (en) * 2024-02-28 2026-07-28 Pioneer Hi-Bred International, Inc. Soybean line 5PDBH03
US12696865B1 (en) * 2024-02-28 2026-08-04 Pioneer Hi-Bred International, Inc. Soybean line 5PLYF71
CN121759452A (zh) * 2024-09-30 2026-03-31 北京福元医药股份有限公司 用于抑制MARC1基因表达的siRNA及其缀合物和用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
JP4335310B2 (ja) 1995-06-07 2009-09-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20030130186A1 (en) 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US9181551B2 (en) * 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CA2487274A1 (en) 2002-05-06 2003-11-13 Nucleonics Inc. Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
US8017762B2 (en) 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
EP2669377A3 (en) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
US7851615B2 (en) 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
WO2008131419A2 (en) 2007-04-23 2008-10-30 Alnylam Pharmaceuticals, Inc. Glycoconjugates of rna interference agents
EP2229186A2 (en) 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US20110081362A1 (en) * 2008-01-31 2011-04-07 The Brigham And Women's Hospital, Inc. Treatment of cancer
AR090905A1 (es) 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
PL2992098T3 (pl) * 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
WO2014205451A2 (en) 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
EP3865576A1 (en) 2014-12-15 2021-08-18 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
US10835581B2 (en) 2017-11-28 2020-11-17 University of Pittsburgh—of the Commonwealth System of Higher Education Method of treating insulin resistance
EP4541352A3 (en) * 2018-07-06 2025-07-16 Algernon Pharmaceuticals Inc. Compositions and methods for treating non-alcoholic steatohepatitis
SG11202105900UA (en) 2018-12-10 2021-07-29 Amgen Inc CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF
CN110468196B (zh) * 2019-08-20 2020-04-28 南京市第一医院 一种预测氯吡格雷抵抗的生物标志物的应用及其试剂盒
WO2021237097A1 (en) * 2020-05-21 2021-11-25 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting marc1 gene expression

Similar Documents

Publication Publication Date Title
CN113164509B (zh) 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法
TWI880645B (zh) 抑制lpa之基因表現之組合物及方法
JP2023504744A5 (cg-RX-API-DMAC7.html)
JP2021518125A5 (cg-RX-API-DMAC7.html)
JP2019524151A5 (cg-RX-API-DMAC7.html)
US20160289677A1 (en) APOB Antisense Conjugate Compounds
CN117701562A (zh) 用于抑制血管生成素-样3(ANGPTL3)的表达的RNAi剂和组合物以及使用方法
IL300360A (en) RNAi constructs and methods to inhibit MARC1 expression
RU2015154721A (ru) КОМПОЗИЦИИ НА ОСНОВЕ RNAi SERPINA1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
IL310929A (en) Preparations and methods for inhibiting expression of angiopoietin-like protein 3
JP2024538859A5 (cg-RX-API-DMAC7.html)
GB2629679A (en) Dual silencing
CN117070517A (zh) 用于抑制血管紧张素原表达的siRNA、其缀合物和药物组合物及用途
WO2022089486A1 (zh) 抑制PCSK9基因表达的siRNA及其修饰物与应用
KR20150006742A (ko) 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물
JP2022534402A5 (cg-RX-API-DMAC7.html)
WO2023284559A1 (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2023208109A9 (zh) 用于抑制HSD17B13表达的siRNA、其缀合物和药物组合物及其用途
JP2024528701A5 (cg-RX-API-DMAC7.html)
KR20260040626A (ko) 안지오텐시노겐을 표적으로 하는 올리고뉴클레오티드 및 이의 용도
CN119343449A (zh) 用于抑制angptl3表达的rnai剂及其应用
JP2025512771A5 (cg-RX-API-DMAC7.html)
JP2025517965A5 (cg-RX-API-DMAC7.html)
RU2822093C1 (ru) Нуклеиновые кислоты для ингибирования экспрессии lpa в клетке
RU2024107655A (ru) Композиции и способы ингибирования экспрессии ангиопоэтин-подобного белка 3 (angptl3)